EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression

Giulia Lanzolla iD, Francesca Saba, Silvia Corrias, Filippo Lixi, Giulia Faa, Alessandro Colleo, Chiara Mura, Gian Luigi Canu, Federico Cappellacci, Alberto Cuccu, Giuseppe Giannaccare, Stefano Mariotti und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.06.2026 · 111 (7) · e1863-e1873

DOI: 10.1210/clinem/dgag037 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.02.2026. Verfasst von Giulia Lanzolla und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari, Cagliari 09100, Ita…. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Cagliari.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This observational investigation aimed to assess the accuracy of a novel score in predicting the onset of overt Graves' orbitopathy (GO) in patients with Graves' disease (GD). Materials and methods A total of 156 consecutive patients with GD without GO were enrolled. As control group, 45 patients with non-autoimmune hyperthyroidism were included. At baseline, an ophthalmological evaluation was performed, including (1) visual function tests and (2) orbital ultrasound. After 24 months, the occurrence of GO was assessed in all patients.

Results

At baseline, a score from 0 to 3 and a score from 0 to 5 were assigned based on the results of visual function tests and the results of orbital ultrasound, respectively. The scores were combined into an overall FUnctional and MOrphological risk score (FUMO score) (0-8 points), classifying patients as low risk (score 0-2) or medium-high risk (score 3-8). After 24 months, the 2 risk groups were compared for differences in (1) presence/absence of GO and (2) GO activity and severity. Patients in the medium-high risk group developed overt GO more frequently than those in the low-risk group. Additionally, GO was more frequently active and moderate-to-severe in medium-high risk patients. Multiple logistic regression showed that TRAb levels and FUMO were the strongest independent predictors of GO, with higher FT3 and smoking habit levels also conferring increased risk. The model demonstrated good calibration and discrimination (AUC = 0.84; P < .0001), with high positive (73%) and negative (72%) predictive value.

Conclusion

Subclinical ocular alterations can predict the progression of GO in patients with GD. The FUMO score, particularly when combined with TRAb and FT3 levels, reliably identifies patients at risk of developing overt GO, supporting its use for early risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyGraves DiseaseHumansFemaleMaleAdultDisease ProgressionMiddle AgedPrognosisSeverity of Illness IndexFollow-Up StudiesPredictive Value of TestsUltrasonographyRisk Factors

Stichwörter der Autor:innen

Graves' diseaseGraves' orbitopathysubclinical ocular diseasethyroid autoimmunitythyroid eye disease

Autor:innen und Institutionen

  • Department of Medical Sciences and Public Health, Endocrinology Unit, University of Cagliari and University Hospital of Cagliari, Cagliari 09100, Italy.
  • Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari 09124, Italy.
  • Department of Surgical Sciences, Surgery Unit, University of Cagliari and University Hospital of Cagliari, Cagliari 09100, Italy.
  • Eye Clinic, University Hospital of Cagliari, Cagliari 09124, Italy.

ORCID-Profile: Giulia Lanzolla

Förderung

  • University of Cagliari

Zitieren

APA

Lanzolla, G., Saba, F., Corrias, S., Lixi, F., Faa, G., Colleo, A., Mura, C., Canu, G. L., Cappellacci, F., Cuccu, A., Giannaccare, G., Mariotti, S., & Boi, F. (2026). Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression. The Journal of Clinical Endocrinology & Metabolism, 111(7), e1863-e1873. https://doi.org/10.1210/clinem/dgag037

Vancouver

Lanzolla G, Saba F, Corrias S, Lixi F, Faa G, Colleo A, et al. Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression. The Journal of Clinical Endocrinology & Metabolism. 2026;111(7):e1863-e1873. doi:10.1210/clinem/dgag037

BibTeX
@article{Lanzolla2026,
  author = {Lanzolla, Giulia and Saba, Francesca and Corrias, Silvia and Lixi, Filippo and Faa, Giulia and Colleo, Alessandro and Mura, Chiara and Canu, Gian Luigi and Cappellacci, Federico and Cuccu, Alberto and Giannaccare, Giuseppe and Mariotti, Stefano and Boi, Francesco},
  title = {Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {7},
  pages = {e1863--e1873},
  doi = {10.1210/clinem/dgag037}
}
Kostenlos starten →